BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Week In Review | Sep 28, 2018
Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies despite...
BC Innovations | Feb 9, 2018
Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
BC Extra | Jan 26, 2018
Clinical News

After Phase III results, AZ's COPD combo heading for submissions

AstraZeneca plc (LSE:AZN; NYSE:AZN) said triple combination therapy PT010 met six of seven primary endpoints evaluating lung function in the Phase III KRONOS trial to treat moderate to very severe chronic obstructive pulmonary disease. The...
BC Week In Review | Oct 27, 2017
Clinical News

Boehringer and Anthem begin real-world COPD trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Anthem Inc. (NYSE:ANTM) with its outcomes research subsidiary HealthCore Inc. have begun enrolling patients in a real-world study evaluating the effect of Stiolto Respimat tiotropium/olodaterol on the occurrence of...
BC Extra | Oct 5, 2017
Clinical News

Boehringer, Anthem begin real-world COPD trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) and Anthem Inc. (NYSE:ANTM) and its outcomes research subsidiary HealthCore Inc. have begun enrolling patients in a real-world study evaluating the effect of Stiolto Respimat tiotropium/olodaterol on the occurrence of...
BC Week In Review | Sep 22, 2017
Clinical News

GSK preparing submissions for Nucala in COPD

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) plans to submit regulatory applications this half for Nucala mepolizumab (SB-240563) to treat chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype after reporting mixed data from the double-blind, international Phase...
BC Week In Review | Sep 15, 2017
Clinical News

Sanofi, Regeneron report Phase III asthma readout for Dupixent

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported top-line data from the Phase III LIBERTY ASTHMA QUEST trial in 1,902 patients with uncontrolled, persistent asthma showing that Dupixent dupilumab (REGN668, SAR231893) met the co-primary...
BC Extra | Sep 11, 2017
Clinical News

Regeneron falls on Phase III asthma readout for Dupixent

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Dupixent dupilumab met the co-primary endpoints in the Phase III LIBERTY ASTHMA QUEST trial to treat uncontrolled, persistent asthma. However, the data failed to impress investors...
BC Week In Review | Aug 11, 2017
Clinical News

GSK, Innoviva seek expanded Relvar Ellipta label

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Innoviva Inc. (NASDAQ:INVA) submitted to EMA an application to expand the label for Relvar Ellipta fluticasone furoate/vilenterol (GW685698/GW64244) to treat patients whose asthma is already adequately controlled on an inhaled...
Items per page:
1 - 10 of 55